methylcephaeline
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2025 (NCT07016321)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Entamoeba histolyticaINHIBITOR
Entamoeba histolytica
Chemistry & pharmacology
Loading structure…
SMILES
Cl.Cl.CC[C@H]1CN2CCC3=C(C=C(OC)C(OC)=C3)[C@@H]2C[C@@H]1C[C@H]4NCCC5=CC(OC)=C(OC)C=C45- Mol. weight
- 553.561 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSU52OG12P96 ↗
- ChEMBLCHEMBL513000 ↗
- ChEMBLCHEMBL50588 ↗
- ChEMBLCHEMBL493439 ↗
Also known as
- cephaeline methyl ether
- emetin
- emetine
- emetine
- (-)-emetine
- emetine dihydrochloride
- emetine dihydrochloride
- emetine dihydrochloride
- emetine dihydrochloride
- emetine hydrochloride
- emetine hydrochloride
- emetine hydrochloride
- ipecine
- methylcephaeline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07016321 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2025 | Johns Hopkins University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1